Rowing-Based Exercise Intervention on Health and Quality of Life in Breast Cancer Survivors
NCT07919730, Not applicable, Completed, Università Cattolica di Milano
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Rowing-Based Exercise Intervention on Health and Quality of Life in Breast Cancer Survivors | ClinicalTrials.gov |
| NCT number | NCT07919730 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 20 participants, actual | ClinicalTrials.gov |
| Lead sponsor | Università Cattolica di Milano | ClinicalTrials.gov |
| Conditions | Breast Cancer | ClinicalTrials.gov |
| Interventions | Behavioral Rowing-based exercise therapy program | ClinicalTrials.gov |
| First posted | 2026-11-05 | ClinicalTrials.gov |
| Last updated | 2026-11-10 | ClinicalTrials.gov |
Registered outcomes 12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change in estimated maximal aerobic capacity (VO2max) | Baseline (T0), 3 months (T1), and 6 months (T2) | VO2max is estimated from a direct submaximal exercise test on a cycle ergometer, consisting of three 4-minute stages at progressively increasing workloads (30 to 70 W, depending on initial fitness) at 50-60 rpm. Oxygen uptake and heart rate are measured continuously with a portable metabolic analyzer (K5, COSMED). The test is stopped at 85% of age-predicted maximum heart rate or a Borg CR10 rating of perceived exertion of 7 or higher. Change from baseline is evaluated at 3 and 6 months. | ClinicalTrials.gov |
| Primary | Change in health-related quality of life (EORTC QLQ-C30) | Baseline (T0), 3 months (T1), and 6 months (T2) | Health-related quality of life is assessed with the EORTC QLQ-C30, a 30-item self-administered cancer-specific questionnaire. It includes a global health status/quality of life scale, five functional scales (physical, role, emotional, cognitive, and social functioning), three symptom scales (fatigue, pain, nausea/vomiting), and single items on cancer-related symptoms and problems (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). All scales are scored from 0 to 100; higher scores on the global health status and functional scales indicate better functioning, while higher scores on the symptom scales indicate more severe symptoms. Change from baseline is evaluated at 3 and 6 months. | ClinicalTrials.gov |
| Primary | Change in self-esteem (Rosenberg Self-Esteem Scale) | Baseline (T0), 3 months (T1), and 6 months (T2) | The Rosenberg Self-Esteem Scale consists of 10 statements assessing self-worth and satisfaction with oneself. Positively worded items are scored from 0 (strongly disagree) to 3 (strongly agree); negatively worded items are reverse-scored. | ClinicalTrials.gov |
| Primary | Change in enjoyment of physical activity (PACES) | Baseline (T0), after each training session, 3 months (T1), and 6 months (T2) | The Physical Activity Enjoyment Scale (PACES) consists of 16 items rated on a 5-point Likert scale and assesses the level of enjoyment experienced during physical activity. It is administered at baseline and after each training session. | ClinicalTrials.gov |
| Primary | Metabolic responses to rowing (oxygen uptake and heart rate) | During selected rowing sessions in the last three months of the intervention (months 4 to 6) | During selected rowing sessions, participants are monitored on a rotational basis using a portable metabolic analyzer (K5, COSMED), which continuously records oxygen uptake and heart rate through indirect calorimetry. | ClinicalTrials.gov |
| Secondary | Change in maximal isometric handgrip strength | Baseline (T0), 3 months (T1), and 6 months (T2) | Maximal isometric handgrip strength is measured bilaterally (right and left hand) with a hydraulic hand dynamometer (JAMAR). Participants perform three maximal voluntary contractions of up to 3 seconds per hand, separated by 60 seconds of rest. | ClinicalTrials.gov |
| Secondary | Change in flexibility (V-Sit-and-Reach and Back Scratch tests) | Baseline (T0), 3 months (T1), and 6 months (T2) | Flexibility is assessed with the V-Sit-and-Reach Test and the Back Scratch Test. | ClinicalTrials.gov |
| Secondary | Change in body composition (body fat percentage) | Baseline (T0), 3 months (T1), and 6 months (T2) | Skinfold thickness is measured with a Harpenden caliper at three sites (triceps, suprailiac, anterior thigh). Body density is estimated with the Jackson and Pollock three-site method, and body fat percentage is calculated with the Siri equation. | ClinicalTrials.gov |
| Secondary | Change in anthropometric measures (body mass index, waist, hip, and upper-limb | Baseline (T0), 3 months (T1), and 6 months (T2) | Height and body weight are measured with a mechanical scale and a portable stadiometer to calculate body mass index (kg/m2). Waist circumference is measured at the midpoint between the lower costal margin and the iliac crest, and hip circumference at the widest part of the hips. Upper-limb circumference is measured at seven points along the upper arm and forearm. | ClinicalTrials.gov |
| Secondary | Change in functional and symptom scales of quality of life (EORTC QLQ-C30) | Baseline (T0), 3 months (T1), and 6 months (T2) | The EORTC QLQ-C30 assesses five functional scales (physical, role, emotional, cognitive, and social functioning), three symptom scales (fatigue, pain, nausea/vomiting), and single items on cancer-related symptoms and problems (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). Scores range from 0 to 100. | ClinicalTrials.gov |
| Other | Number of exercise-related adverse events (safety) | From enrollment to 6 months | The number of adverse events related to physical exercise, the underlying disease, and its treatments is recorded throughout the intervention. | ClinicalTrials.gov |
| Other | Adherence to the program | From the start of the intervention to 6 months | Adherence is defined as the percentage of scheduled training sessions completed by each participant. It is considered satisfactory if at least 75% of scheduled sessions are completed | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 19
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|---|---|
| 8433390 | BACKGROUND | PubMed |
| 9653497 | BACKGROUND | PubMed |
| 11708692 | BACKGROUND | PubMed |
| 16098120 | BACKGROUND | PubMed |
| 16430682 | BACKGROUND | PubMed |
| 21624928 | BACKGROUND | PubMed |
| 23915045 | BACKGROUND | PubMed |
| 24419734 | BACKGROUND | PubMed |
| 25160991 | BACKGROUND | PubMed |
| 25882745 | BACKGROUND | PubMed |
| 28376231 | BACKGROUND | PubMed |
| 29933309 | BACKGROUND | PubMed |
| 32337494 | BACKGROUND | PubMed |
| 32659900 | BACKGROUND | PubMed |
| 32960338 | BACKGROUND | PubMed |
| 32974802 | BACKGROUND | PubMed |
| 33379177 | BACKGROUND | PubMed |
| 34281126 | BACKGROUND | PubMed |
| 35879447 | BACKGROUND | PubMed |
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)